Tumori Journal · 2015 · 20 citations · 13 references
MedicineOncologyPharmacologyChemotherapyNeoplasiaTumor ProgressionCancer ProgressionChemotherapy ResistanceLung CancerMalignant NeoplasmsTherapeutic ResistanceAcquired Resistance MechanismsComplete Response AssessmentEgfr InhibitionLung AdenocarcinomaNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentSmall Cell Lung Cancer TherapySmall Cell Lung Cancer Treatment
First-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for patients with advanced non-small cell lung cancer who were selected on the basis of EGFR mutations have improved the progression-free survival with acceptable toxicity compared to standard chemotherapy. However, acquired resistance to EGFR-TKIs has been identified as an important clinical problem. Transformation to small cell lung cancer (SCLC) is a rare mechanism of resistance to EGFR-TKI therapy. We describe the case of a 61-year-old man who presented transformation from adenocarcinoma to SCLC as the manifestation of acquired resistance after EGFR-TKI treatment. He underwent chemotherapy with etoposide and cisplatin and achieved a complete response.
13
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +15